Radioligand Therapy Boosts Survival in Metastatic CRPC

(MedPage Today) -- An investigational radioligand therapy targeting prostate-specific membrane antigen (PSMA) delayed disease progression and improved survival for patients with metastatic castration-resistant prostate cancer (CRPC), a phase III...